MedTrace Logo

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 967

Last updated 2015-05-19

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

Conditions

  • Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG

AIN457 150mg

(1 injection per dose) and placebo to secukinumab 150 mg

DRUG

AIN457 300mg

secukinumab 150 mg (2 injections per dose)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States
  • Austria
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Poland
  • Singapore
  • Slovakia
  • Switzerland
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01406938 on ClinicalTrials.gov